[1] |
Correll CU,Robinson DG,Schooler NR,et al.Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders:baseline results from the RAISE-ETP study[J].JAMA Psychiatry,2014,71(12):1350-1363.
|
[2] |
Tiihonen J,Lonnqvist J,Wahlbeck K,et al.No mental health without physical health[J].Lancet,2011,377(9766):611.
|
[3] |
Samaras K,Correll CU,Mitchell AJ,et al.Diabetes risk potentially underestimated in youth and children receiving antipsychotics[J].JAMA Psychiatry,2014,71(2):209-210.
|
[4] |
Mizuno Y,Suzuki T,Nakagawa A,et al.Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia:a systematic review and meta-analysis[J].Schizophr Bull,2014,40(6):1385-1403.
|
[5] |
Maayan L,Vakhrusheva J,Correll CU.Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities:a systematic review and meta-analysis[J].Neuropsychopharmacology,2010,35(7):1520-1530.
|
[6] |
Ikegami M,Ikeda H,Ohashi T,et al.Olanzapine-induced hyperglycemia:possible involvement of histaminergic,dopaminergic and adrenergic functions in the central nervous system[J].Neuroendocrinology,2013,98(3):224-232.
|
[7] |
Volpato AM,Zugno AI,Quevedo J.Recent evidence and potential mechanisms underlying weight gain and insulin resistance due to atypical antipsychotics[J].Rev Bras Psiquiatr,2013,35(3):295-304.
|
[8] |
Cohen P,Levy JD,Zhang Y,et al.Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switch[J].Cell,2014,156(1/2):304-316.
|
[9] |
Rosenwald M,Perdikari A,Rulicke T,et al.Bi-directional interconversion of brite and white adipocytes[J].Nat Cell Biol,2013,15(6):659-667.
|
[10] |
Dempersmier J,Sambeat A,Gulyaeva O,et al.Cold-inducible Zfp516 activates UCP1 transcription to promote browning of white fat and development of brown fat[J].Mol Cell,2015,57(2):235-246.
|
[11] |
Blagosklonny MV. TOR-centric view on insulin resistance and diabetic complications:perspective for endocrinologists and gerontologists[J].Cell Death Dis,2013,4:e964.
|
[12] |
Fukuda D,Aikawa E,Swirski FK,et al.Notch ligand delta-like 4 blockade attenuates atherosclerosis and metabolic disorders[J].Proc Natl Acad Sci U S A,2012,109(27):E1868-1877.
|
[13] |
Bi P,Shan T,Liu W,et al.Inhibition of Notch signaling promotes browning of white adipose tissue and ameliorates obesity[J].Nat Med,2014,20(8):911-918.
|
[14] |
Bartelt A,Heeren J.Adipose tissue browning and metabolic health[J].Nat Rev Endocrinol,2014,10(1):24-36.
|
[15] |
Pajvani UB,Qiang L,Kangsamaksin T,et al.Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability[J].Nat Med,2013,19(8):1054-1060.
|
[16] |
Pajvani UB,Shawber CJ,Samuel VT,et al.Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner[J].Nat Med,2011,17(8):961-967.
|